Real people, real stories For many, oxygen therapy has redefined their ability to participate in life's most meaningful moments. A retired teacher now leads an ...

(HKEX: 02162)�("Keymed" or the "Company") today announced that the prestigious medical journal Nature Medicine has published the results from the Phase III trial of its independently developed�IL-4Ra ...

Trevi Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing the investigational therapy Haduviotm (oral nalbuphine ER) for the treatment of chronic cough in patients with ...

Each of these trials had data analyses that were very important to advancing the clinical development plan of Haduvio. Let me briefly review each of these key readouts. In December, we readout ...

Trevi Therapeutics (($TRVI)) has held its Q4 earnings call. Read on for the main highlights of the call. Trevi Therapeutics’ recent earnings call ...

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary ...

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the completion of a successful pre-NDA meeting with the U.S. Food and ...

Trevi Therapeutics is a clinical-stage biopharmaceutical company focused on developing Haduvio (oral nalbuphine extended-release) to treat chronic cough in patients with idiopathic pulmonary ...

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary ...

Pre-Open Stock Movers: Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) 54% LOWER; announced that the U.S. Food and Drug... ByInvesting.com • May 25, 2022 After-Hours Stock Movers 05/24: Wendy's ...

Each of these trials had data analyses that were very important to advancing the clinical development plan of Haduvio. Let me briefly review each of these key readouts. In December, we read out ...

Each of these trials had data analyses that were very important to advancing the clinical development plan of Haduvio. Let me briefly review each of these key readouts. In December, we read out ...